UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2013

GENVEC, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (240) 632 0740

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INFORMATION TO BE INCLUDED IN THE REPORT

Section 1 – Registrant’s Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

On February 12, 2013, GenVec, Inc. (“GenVec”) and Novartis Institutes for Biomedical Research Inc. (“Novartis”) entered into an amendment (the “Amendment”) to the Research Collaboration and License Agreement that was entered into on January 13, 2010 (the “Agreement”) with respect to GenVec’s preclinical hearing loss and balance disorders program.

Pursuant to the terms of the Amendment, the Agreement has been amended to extend the research collaboration period through January 13, 2014, subject to Novartis’ existing rights of termination under the Agreement, and to provide for continued Novartis funding of research at GenVec during the extended research collaboration period.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.